Free Trial

State Street Corp Sells 262,022 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

GoodRx logo with Medical background

State Street Corp lessened its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 23.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 849,470 shares of the company's stock after selling 262,022 shares during the quarter. State Street Corp owned approximately 0.22% of GoodRx worth $5,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of GDRX. Charles Schwab Investment Management Inc. raised its holdings in GoodRx by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company's stock worth $3,332,000 after purchasing an additional 26,262 shares during the period. Raymond James & Associates increased its position in GoodRx by 212.6% in the third quarter. Raymond James & Associates now owns 394,006 shares of the company's stock worth $2,734,000 after buying an additional 267,951 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its stake in shares of GoodRx by 260.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company's stock worth $308,000 after buying an additional 32,104 shares during the period. Marshall Wace LLP purchased a new position in shares of GoodRx during the 2nd quarter valued at about $843,000. Finally, Rubric Capital Management LP grew its stake in shares of GoodRx by 76.5% during the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company's stock valued at $29,147,000 after acquiring an additional 1,619,748 shares during the period. Institutional investors own 63.77% of the company's stock.

GoodRx Price Performance

NASDAQ GDRX traded up $0.10 during trading on Friday, hitting $4.62. 842,536 shares of the stock traded hands, compared to its average volume of 1,419,801. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 12-month low of $4.09 and a 12-month high of $9.26. The firm has a 50-day simple moving average of $5.09 and a 200-day simple moving average of $6.81. The company has a market capitalization of $1.76 billion, a P/E ratio of -154.00, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29.

Analyst Ratings Changes

GDRX has been the topic of a number of recent analyst reports. Citigroup decreased their target price on shares of GoodRx from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. Barclays decreased their price objective on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Monday, November 11th. Morgan Stanley lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 17th. Finally, Mizuho started coverage on GoodRx in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.37.

Check Out Our Latest Stock Report on GoodRx

About GoodRx

(Free Report)

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Featured Stories

Institutional Ownership by Quarter for GoodRx (NASDAQ:GDRX)

Should You Invest $1,000 in GoodRx Right Now?

Before you consider GoodRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.

While GoodRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines